It's a pivotal moment for cell therapy. New trials, breakthrough data, major acquisitions and regulatory shifts are ...

The Gates Foundation is doubling down on its support for women's health research, pumping $2.5 billion between now and the ...

Around 240,000 people are expected to be offered Mounjaro over the next three years, according to NICE, which has recommended ...

Nalvee marks a return to the market for a dydrogesterone-only product after an absence of 17 years, and can be used in ...

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...

Grant funding calls are often over-subscribed and success rates can be low. Excellent applications sometimes fail to be ...

Pharma 4.0 is no longer a future ambition; it’s the baseline. The ability to operate with real-time data, integrated systems, ...

As excitement builds around GLP-1s and their expanding list of potential indications, the conversation is shifting from hype ...

Don't fall behind. Take a step toward becoming indispensable to your organization by attending our no-cost* LEAN Cell & Gene Boston Summit on Monday, September 22, conveniently planned just one day ...

The list of bodies that have been ousted from Advisory Committee on Immunization Practices (ACIP) workgroups includes ...

The UK has started a 'world-first' gonorrhoea vaccination programme that is designed to prevent thousands of cases and save ...

Vertex already has FDA approval for NaV1.8 inhibitor Journavx (suzetrigine) in acute pain, with late-stage trials on the go ...